ATC Group: N06BA14 Solriamfetol

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N06BA14 in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N06 Psychoanaleptics
3 N06B Psychostimulants, agents used for ADHD and nootropics
4 N06BA Centrally acting sympathomimetics
5 N06BA14

Active ingredients in N06BA14

Active Ingredient

The mechanism(s) of solriamfetol to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea has not been fully characterised. However, its efficacy could be mediated through its activity as a dopamine and norepinephrine reuptake inhibitor (DNRI).

Related product monographs

Document Type Information Source  
 SUNOSI Film-coated tablet MPI, EU: SmPC European Medicines Agency (EU)
 SUNOSI Film-coated tablet MPI, US: SPL/PLR FDA, National Drug Code (US)

United States medicines

Medicines classified under this ATC code globally

Austria (AT)

Croatia (HR)

Estonia (EE)

Finland (FI)

France (FR)

Ireland (IE)

Israel (IL)

Italy (IT)

Lithuania (LT)

Poland (PL)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.